Sprenger-Svačina, Alina
Klein, Ines
Svačina, Martin K. R.
Bobylev, Ilja
Kohle, Felix
Schneider, Christian
Schweitzer, Finja
Piekarek, Nadin
Barham, Mohammed
Vehreschild, Maria J. G. T.
Lehmann, Helmar C.
Farowski, Fedja
Funding for this research was provided by:
Universitätsklinikum Köln
Article History
Received: 30 November 2023
Accepted: 21 April 2024
First Online: 31 May 2024
Declarations
:
: Animal experiments were approved by and carried out according to the guidelines of local state authorities (Landesamt für Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen [LANUV]).
: A. Sprenger-Svačina, I. Klein, M.K.R. Svačina, I. Bobylev, C. Schneider, F. Schweitzer, M. Barham, N. Piekarek, F. Farowski report no disclosures. F. Kohle is supported by the Cologne Clinician Scientist Program (CCSP) / Faculty of Medicine / University of Cologne, funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (Project No. 413543196). H.C. Lehmann received honoraria for speaking and advisory board engagements or academic research support by Akcea, Alnylam, Biogen, Celgene, CSL Behring, Grifols, Gruenenthal, LFB Pharma, Takeda and UCB. M.J.G.T. Vehreschild received research grants from 3 M, Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics, Takeda Pharmaceutical as well as speaker fees and/or consulting fees from Alb Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Basilea, Bio-Mérieux, DaVolterra, Farmak International Holding GmbH, Ferring, Gilead Sciences, Immunic AG, MaaT Pharma, Merck/MSD, Pfizer, Roche, Organobalance, SocraTec R&D GmbH.